All the elements are in place for China's leap into the global biotech sector.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
I would like to thank Mao Mao (Merck), Edmund Tsuei (Roche), Tom Bliss (Amgen), Zemin Zhang and Joe McCracken (Genentech), Gunther Winkler, Huo Li and David Yang (Biogen Idec), Ling Su, Zhinan Xia, Zhijian Lu and Xiaoxiang Chen (Wyeth), Yupeng He (Abbott), Yuling Li (HGSI), Steven Ling Feng Liu (Fudan University), James Cai and Tony Ling (AstraZeneca), Weijun Li (Bayer), Mak Jawadekar (Pfizer), Zhu De-Min and Qu Xianlu (Merck), Matthew Levy and Chris Song (Applied Biosystems), Lance Han (Cyagen), Fung Ming Chiu (CUHK), Benjamin Lee and Bernard Chan (CDE Limited), Stephen Ip (TaiGen), Stephen Lam (HKSTP), Jack Lu (AQchem), Chen Chun-Lin (Medicilon/MPI) and Jintao Zhang (Medicilon), Kevin Zhou (SSTK), Zhu Huaxing (SinoBio), Brian Zhang (NovoMed), Michael Xu (PanAsia Bio), Jian Ni (Human Antibodomics), Xumu Zhang (Chiral Quest), William Pan and Faming Zhang (Crown Bioscience), Xian-Ping Lu and XQ Ning (Chipscreen), Ying Luo (Shanghai Genomics), Yaozhou Shi (Shanghai BioChip), Angela Wong (Wuxi PharmaTech), Albert Yu and Terence Lau (Hai Kang Life), Howard Young (NCI), Ching Ching Wu and Huiling Wei (Purdue University), Joseph Li (University of Utah), Reinhard Ebner (Avalon Pharmaceuticals), Yihan Wang (Ariad) and Edward Chang (Dyax) for their excellent comments and suggestions.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wong, G. Developing China's homegrown biotechnology workforce. Nat Biotechnol 26, 353–354 (2008). https://doi.org/10.1038/nbt0308-353
Issue Date:
DOI: https://doi.org/10.1038/nbt0308-353